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ADVANCEMENTS IN PULMONARY ARTERIAL HYPERTENSION 
TREATMENT 
ASHANK BAINS 
ABSTRACT 
 Pulmonary arterial hypertension is a rare, chronic disease characterized by 
progressive remodeling of the pulmonary vasculature. Historically, prognosis has been 
very poor with relatively low 3-year survival rates. Common symptoms include fatigue 
and shortness of breath upon exercise, chest pain, and syncope. Patients exhibit increased 
pressure and resistance in pulmonary arteries due to fibrosis, vessel narrowing, and 
elevated levels of vasoconstrictive agents; diagnosis is confirmed by right heart 
catheterization. Reduced blood flow through the pulmonary vasculature not only reduces 
the amount of oxygenated blood available for the systemic circulation, but increases 
afterload on the right ventricle and, if left untreated, ultimately causes right ventricular 
heart failure. 
 In the past, few medications were available to pulmonary arterial hypertension 
patients. However, recent advancements in our molecular understanding of the disease 
have led to the development of new therapeutic options that show promise of slowing, or 
in some cases reversing, disease progression. Currently available treatments have been 
shown to significantly improve 3-year survival rates and help promote a better quality of 
life for patients. While an exact molecular or genetic mechanism of disease progression is 
not yet known, several studies have noted the presence of dysfunctional endothelial cells 
and an imbalance in molecular modulators of the pulmonary vasculature. Specifically, 
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patients exhibit chronically low levels of vasodilating agents such as prostacyclin and 
nitric oxide. In addition, there is a heightened vasoconstrictive effect due to elevated 
endothelin-1 and thromboxane A2. Drugs have been developed to target these signaling 
pathways and show considerable promise and efficacy for managing pulmonary 
hypertension in patients. Although these therapeutics have been shown to significantly 
improve survival rates and symptoms, many have complex and inconvenient 
administration protocols and a host of adverse side effects. Moreover, many require 
monitoring or frequent follow up visits due to their off-target effects. Recent innovative 
advancements in pulmonary arterial hypertension pharmaceuticals hope to deliver safe, 
efficacious treatment options to patients debilitated by this chronic disease.  
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Introduction 
 
 Pulmonary arterial hypertension (PAH) is a rare progressive disease with an 
unfortunately poor prognosis. It is a subtype of pulmonary hypertension (PH) impacting 
the pre-capillary vasculature; the WHO has defined several groups of PH based on 
etiology (see Table 1). Typically, PAH has an incidence of 2 cases per million, with 
Idiopathic PAH (formerly named Primary PAH) representing the most common case 
(Humbert et al., 2006; Humbert and Lynch, 2009). The disease is characterized by 
increased pressure in the pulmonary arterial system (mean pulmonary artery pressure 
greater than 25 mmHg, at rest (Barst et al., 2004)) associated with vasoconstrictive 
vascular remodeling, thrombosis in situ, and proliferation of both arterial smooth muscle 
cells and endothelial cells (Farber and Loscalzo, 2004). Increased resistance in the 
pulmonary system ultimately leads to right ventricular heart failure and death; the NIH 
found a median survival rate of 2.8 years following diagnosis, and more recent studies 
have found an untreated 3-year survival rate of only ~67% (Humbert et al., 2010; Benza 
et al., 2012). Several factors have been found that positively correlate with a poor 
prognosis: age above 50, male gender, history of right ventricular dysfunction, decreased 
vasculature capacitance, WHO functional class 3 or 4, hypocapnia, elevated serum N-
terminal brain natriuretic peptide, and others (Sitbon et al., 2002; Mahapatra et al., 2006; 
Fijalkowska et al., 2006; Benza et al., 2010).  
 Historically classified as either primary or secondary pulmonary hypertension, 
multiple classifications of PAH have now been established by the WHO: Idiopathic PAH 
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(IPAH), Familial PAH (FPAH), PAH associated with other diseases (APAH), etc (Table 
2). Functional classes have also been established to assist physicians with diagnostics and 
treatment options (Table 3). Interestingly, the disease has a predominance towards 
women with a female to male ratio as high as 4:1 (Badesch et al., 2010). Mortality rates 
have been found to be higher in adult men, indicating that there may be an underlying 
hormonal component to disease progression (Austin et al., 2009; Mair et al., 2014). 
 Therapies for PAH have been developed to target molecules known to modulate 
pulmonary vasculature pathways; however, drug delivery methods remain inconvenient 
for patients and systemic side effects may cause adverse reactions. Prostacyclin (PGI2), 
endothelin-1 (ET-1), and nitric oxide (NO) pathways (Figure 1) have been of particular 
interest for pharmaceutical companies (Sitbon and Morrell, 2012), but abnormal levels of 
thromboxane A2, serotonin, and vasoactive intestinal peptide have also been found in 
PAH patients (Christman et al., 1992; Hervé et al., 1995; Petkov et al., 2003). PGI2 
asserts its vascular effects through activation of a G-protein coupled receptor (GPCR), 
the IP receptor, promoting vasodilation and inhibiting vascular smooth muscle 
proliferation (Lang and Gaine, 2015). PAH patients commonly have reduced prostacyclin 
synthase expression in pulmonary arteries (Tuder et al., 1999) and overall reduced PGI2 
levels (McLaughlin and McGoon, 2006), making this pathway a rationale target in terms 
of therapeutics. 
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Table 1. Classification of Pulmonary Hypertension by the World Health 
Organization (WHO). Types and subtypes of PH as defined during the Fifth World 
Symposium on Pulmonary Hypertension, 2013. Adapted from Simonneau et al., 2013. 
Group # Description and subtype 
Group 1 Pulmonary arterial hypertension. 
Group 2 Pulmonary hypertension caused by left 
heart disease. 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction  
2.3 Valvular disease 
2.4 Congenital/acquired left heart flow 
tract obstruction and congenital 
cardiomyopathies 
Group 3 Pulmonary hypertension due to chronic 
lung disease/hypoxia.  
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed 
restrictive and obstructive pattern  
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung diseases  
Group 4 Pulmonary hypertension due to chronic 
thromboembolic pulmonary hypertension. 
Group 5 Pulmonary hypertension due to unclear 
multifactorial mechanisms. 
5.1 Hematologic disorders 
5.2 Systemic disorders 
5.3 Metabolic disorders  
5.4 Others 
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Table 2. Types and Subtypes of Pulmonary Arterial Hypertension. Classification of 
PAH as defined during the Fifth World Symposium on Pulmonary Hypertension, 2013. 
Adapted from Simonneau et al., 2013. 
Type Subtype* 
1.1 Idiopathic PAH  
1.2 Heritable PAH 1.2.1 BMPR2 
1.2.2 ALK-1, ENG, SMAD9, CAV1, 
KCNK3 
1.2.3 Unknown 
1.3 Drug and toxin induced PAH  
1.4 PAH associated with other diseases 1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1’ Pulmonary veno-occlusive disease/ 
pulmonary capillary hemangiomatosis 
 
1’’ Persistent pulmonary hypertension of 
the newborn 
 
 
 *BMPR = bone morphogenic protein receptor type II; CAV1 = caveolin-1; ENG = endoglin; 
HIV = human immunodeficiency virus. 
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Table 3. WHO Functional Classes for Pulmonary Hypertension. Clinical 
classifications for severity of PAH. Adapted from Galiè et al., 2009. 
Class Description 
Class 1 Patients with PH but without resulting 
limitations of physical activity. 
Class 2 Patients with PH resulting in slight 
limitations of physical activity. 
Comfortable at rest, but ordinary physical 
activity results in symptoms to appear. 
Class 3 Patients with PH resulting in marked 
limitations of physical activity. 
Comfortable at rest, but less than ordinary 
activity causes symptoms to appear. 
Class 4 Patients with PH resulting in an inability to 
carry on physical activity without the 
occurrence of symptoms. These patients 
routinely develop signs of right heart 
failure. Dyspnea and fatigue may present at 
rest. 
 
 
 Similarly to PGI2, NO is a vasodilator which inhibits vascular smooth muscle 
proliferation and platelet aggregation (McLaughlin and McGoon, 2006). Multiple points 
of intervention are targeted in this pathway: local endothelial cell production of NO 
increases levels of the intracellular secondary messenger cyclic guanosine 
monophosphate (cGMP) and the signal is terminated in pulmonary tissue by 
phosphodiesterase-5 (PDE-5) enzymatically hydrolyzing cGMP. Therapeutics have been 
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developed both to increase cGMP levels and inhibit PDE-5 activity (Lang and Gaine, 
2015). In contrast to PGI2 and NO, ET-1 levels are elevated in PAH patients and may be 
positively correlated with poor prognosis (Rubens et al., 2001). ET-1 has vasoconstrictive 
and proliferative effects on endothelium and vascular smooth muscle, and many ET-1 
antagonists have been developed as therapeutics (McLaughlin and McGoon, 2006). 
Adverse effects of traditional ET-1 receptor antagonists, particularly hepatotoxicity 
(McGoon et al., 2009), require physicians to monitor patients and carefully consider the 
safety profiles of drugs. Over the last decade, many exciting advancements have been 
made in the field of pulmonary hypertension treatment, and hopes are high for improving 
prognosis for patients. In particular, innovations in drug delivery methods and reduction 
of adverse side effects may help with patient adherence and physician utilization, as most 
commonly used therapeutics are not currently available in oral formulation (Lang and 
Gaine, 2015). 
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Figure 1: Major pathways targeted for therapeutic intervention in pulmonary 
arterial hypertension disease progression. From left to right: endothelin-1 (ET-1) 
pathway; nitric oxide (NO) pathway; prostacyclin (PGI2) pathway. Figure taken from 
Sitbon and Morrell, 2012. ERA = ET receptor antagonist; cGMP = cyclic guanosine mono 
phosphate; PDE-5i = phosphodiesterase-5 inhibitor; cAMP = cyclic adenosine mono phosphate; 
SMCs = smooth muscle cells.  
Specific Aims 
The goals of this paper are to provide a concise overview of the current literature defining 
disease pathology and currently utilized therapeutics in pulmonary arterial hypertension. 
In addition, emerging treatment options and therapeutics currently in development will be 
discussed with emphasis on their potential for improving patient prognosis and quality of 
life. Finally, potential genetic mechanisms of therapeutic intervention will be briefly 
discussed as the future of PAH treatment. 
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Therapeutic Pathways in Pulmonary Arterial Hypertension 
 Compared to the systemic circulation, the pulmonary circulation is a low pressure 
system with thin arterial walls and low resistance. The pathobiology of PAH is 
characterized by the dysfunction of a variety of cell types: vascular smooth muscle cells, 
endothelial cells, fibroblasts, and platelets (Humbert et al., 2004), leading to vascular 
remodeling and narrowing of blood vessels. Notably, increased proliferation of smooth 
muscle cells is accompanied by their migration to more distal arteries which do not 
normally have musculature in healthy patients (Humbert et al., 2004). Combined with 
inappropriate levels of vasomodulating molecules causing increased vasoconstriction, 
pressure in the pulmonary system rises well above normal values. The molecular 
mechanism by which smooth muscle cells migrate to smaller, more distal vessels is not 
entirely clear but may involve interactions between several signaling molecules. 
 Endothelial cell dysfunction is thought to be a principal factor in the progression 
of PAH (McLaughlin and McGoon, 2006). Not only is abnormal endothelial cell 
proliferation a major concern as it can cause severe vessel thickening and the formation 
of plexiform lesions (Humbert et al., 2004), there is an imbalance in the production of 
molecules modulating vasoconstriction, molecules modulating smooth muscle cell 
growth, and molecules modulating thrombosis and inflammation. An underlying genetic 
explanation may involve defective growth suppression genes, particularly the 
transforming growth factor beta type 2 receptor (TGF-BR2) gene (Yeager et al., 2001). 
Studies have shown that 90% of plexiform lesions found in the pulmonary vasculature 
have endothelial cells lacking TGF-BR2 expression (Humbert et al., 2004). 
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 In addition to the TGF-BR2 mutation, many other possible genetic markers for 
PAH exist within the TGF-B family. Most notable is the bone morphogenetic protein 
receptor 2 (BMPR2), which forms part of a heteromeric serine/threonine kinase receptor 
found on vascular smooth muscle cells (Liu et al., 1995). Mutations in the gene encoding 
BMPR2 are heavily associated with cases of familial PAH, and it is believed faulty signal 
transduction leads to increased proliferation of smooth muscle cells in pulmonary 
vasculature (McLaughlin and McGoon, 2006). This represents a promising avenue for 
diagnostic markers, as mutations in the BMPR2 gene have been found in 60-80% of 
FPAH patients and in 10-40% of IPAH patients, with the majority of mutations causing a 
nonfunctional protein through premature termination (Humbert et al., 2004; Machado et 
al., 2006). Mutations in other receptors, such as the activin-like kinase type 1 receptor 
(Trembath et al., 2001), and increased expression of serotonin transporters (Eddahibi et 
al., 2001), are also implicated in PAH. However, genetic therapies have remained elusive 
in modern PAH management. The lack of BMPR2 mutations in the majority of IPAH 
cases may implicate that other genes, yet to be identified, are also responsible for the 
disease pathology.  
  The molecular mechanisms underpinning the progression of PAH have received 
a considerable amount of attention in recent years. In terms of therapeutic options, PAH 
patients have elevated levels of the vasoconstrictor ET-1, and reduced vasodilators NO 
and PGI2. Modern therapeutic advances have focused primarily on these three major 
pathways.  
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Endothelin-1 pathway 
 Endothelin-1 is a 21 amino acid polypeptide released by endothelial cells with 
high levels of expression in the pulmonary endothelium (Chester and Yacoub, 2014). ET-
1 levels are mostly regulated at the transcriptional level, as well as by post-translational 
cleavage of the proenzyme (Chester and Yacoub, 2014). These processes are regulated by 
many different factors: hypoxia, shear stress, and growth factors increase ET-1 
production, while PGI2, NO, and high estrogen act to decrease ET-1 levels (Galié et al., 
2004). The effect of estrogen specifically may help explain the gender differences in 
PAH disease progression, and the inhibitory effects of PGI2 and NO on ET-1 synthesis 
indicate a level of cross-talk between the vasomodulating pathways. Interestingly, ligands 
for BMPR2 have been shown to diminish the action of ET-1, suppressing contraction of 
smooth muscle cells upon the activation of the ET-1 receptor (Chester and Yacoub, 
2014), indicating a possible interaction between BMPR2 mutations and ET-1 levels.  
 The ET-1 receptor itself is a GPCR found on vascular smooth muscle cells, 
activation of which triggers a phospholipase C-mediated signal cascade that ultimately 
increases levels of intracellular calcium (Pollock et al., 1995). Binding of ET-1 to its 
receptor on vascular smooth muscles cells causes activation of contractile machinery 
(Chester and Yacoub, 2014), increasing arterial pressure and contributing to the effects of 
pulmonary hypertension.  
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Figure 2: Endothelin-1 pathway signaling cascade linked to pulmonary vascular 
smooth muscle cell contraction, proliferation, and apoptosis. Activation of the ET-1 
pathway causes contraction, cellular migration, and proliferation, while suppressing 
apoptosis. Figure taken from Chester and Yacoub, 2014. ETA = ET receptor A; ETB = ET 
receptor B; PLC = phospholipase C; IP3 = inositol 1,4,5-triphosphate; DAG = diacylglycerol; 
PK = protein kinase C; RAF = rapidly accelerated fibrosarcoma protein; MAPKs = mitogen 
activated protein kinases; cSRC = cytosolic tyrosine kinase; PI3K-y = phosphatidylinositol 3-
kinase gamma; SHC = Src homology 2 domain-containing; GRB2 = growth factor receptor-
bound protein 2; SOS = son of sevenless protein; RAS = rat sarcoma protein; RTK = receptor 
tyrosine kinase. 
 
The receptor also has a role in regulating smooth muscle proliferation and cell migration 
(Figure 2), contributing to the vascular remodeling seen in PAH. ET-1 has been 
extensively studied as an agent for PAH therapy: PAH patients have elevated levels of 
ET-1 due to both increased production and reduced clearance (Stewart et al., 1991). 
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Nitric Oxide pathway 
 NO is a potent vasodilator produced in pulmonary epithelium and vascular 
endothelial cells. It is synthesized by the enzymatic action of NO synthase, activity of 
which is regulated transcriptionally and by post-translational modifications (Michelakis, 
2004). Local NO levels play an important role in the vasodilation of pulmonary 
vasculature and ventilation-perfusion matching, and may delay the progression of 
vascular remodeling seen in PAH (Sparacino-Watkins et al., 2012). Regulation of the NO 
pathway is rather complicated, involving secondary messenger signal cascades and the 
action of multiple enzymes, such as guanylate cyclase and phosphodiesterase (PDE) 
(Figure 3). Furthermore, these enzymes may have interactions with proteins in the TGF 
family (Kolosionek et al., 2009), indicating that there may be an underlying genetic 
dysfunction affecting the NO pathway in PAH patients. While there are currently 11 
known PDE isoforms with varying tissue distribution, they all act to degrade cyclic 
mononucleotides (Barst, 2008) and terminate the signaling cascade initiated by substrates 
such as NO. Antagonizing generalized PDE action may impact other signaling pathways 
that rely on cGMP. In the lungs, PDE-5 is the primary isoform terminating the NO signal 
(Ghofrani et al., 2004), making inhibitors of this specific protein an attractive target for 
PAH therapy. While PDE-5 inhibitors (PDE-5i) have been shown to reduce the elevated 
pulmonary arterial pressure and vasoconstriction associated with hypoxia (Zhao et al., 
2001), further studies are needed on their efficacy on reversing the adverse vascular 
remodeling seen in PAH. 
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Figure 3: Nitric Oxide pathway signaling cascade linked to vasodilation of the 
pulmonary vasculature. Activation of the NO pathway by oxygen and alveolar 
ventilation decreases contractile force in pulmonary vascular smooth muscle cells. The 
signal is terminated by the action of phosphodiesterase. Figure taken from Ghofrani et al., 
2004. NOS = NO synthase; NO = nitric oxide; cGMP = cyclic guanylate monophosphate; PDE 
= phosphodiesterase. 
 
Added benefits of PDE-5 inhibitor therapy include a well documented safety profile and 
lack of some of the serious systemic side effects seen in other PAH medications.  
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Prostacyclin pathway 
 Prostacyclin, or prostaglandin I2 (PGI2), is produced by endothelial cells and acts 
by increasing intracellular levels of the secondary messenger adenosine monophosphate 
(cAMP) (McLaughlin and McGoon, 2006). Activation of the PGI2 pathway causes 
vasodilation of the pulmonary vasculature, as well as decreased platelet aggregation and 
reduced proliferation of vascular smooth muscle cells (Humbert et al., 2004). PAH 
patients have been shown to have markedly reduced levels of both PGI2 and prostacyclin 
synthase (Tuder et al., 1999), the enzyme responsible for producing PGI2 from 
arachidonic acid (Figure 4). The PGI2 receptor, or IP receptor, has been identified as a 
potential target for PAH therapy, but limitations of current therapeutics have caused 
widespread underutilization of prostanoid therapy (Farber et al., 2011). Higher levels of 
thromboxane A2 are noted in PAH patients (Christman et al., 1992) and may be related to 
dysfunction in the PGI2 synthesis pathway, contributing to the elevated pulmonary 
arterial pressure. 
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Figure 4: Synthesis pathway of prostacyclin. Membrane arachidonic acid is liberated 
by phospholipase A2 and ultimately converted to prostacyclin in endothelial cells by 
enzymatic activity. Figure taken from Mitchell et al., 2015. AA = arachidonic acid; PGH2 
= prostaglandin; PGI2 = prostacyclin; PGE2 = prostaglandin E2. 
 
Current Treatments 
Lifestyle  
 Special care must be taken by PAH patients in daily activities due to their reduced 
effective pulmonary circulation. With that said, exercise should not be avoided 
altogether: a small study found that exercise and physical training had an overall positive 
effect on quality of life on PH patients (Mereles et al., 2006). Caution must be taken 
before strenuous exercise, as increased oxygen demand may cause life-threatening 
syncope (McLaughlin and McGoon, 2006); patients should cease activity if symptoms 
occur. In addition, patients with advanced PAH should avoid ascending to high altitudes 
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as it may cause hypoxia and subsequent worsening of pulmonary vasoconstriction 
(Moudgil et al., 2005). Supplemental oxygen therapy is indicated for patients with a mean 
arterial oxygen saturation below 90% (McLaughlin and McGoon, 2006), except in 
patients with Eisenmenger syndrome (Sandoval et al., 2001).  
 Female patients must take extreme caution during pregnancy, labor, and even the 
postpartum period. Maternal changes in hemodynamics and increased oxygen demand 
during pregnancy and childbirth can cause devastating and potentially fatal effects in 
PAH patients (Weiss et al., 1996). Even with modern advancements in treatment options, 
maternal mortality rates in women with PAH remain high, with most deaths occurring 
within the first month following delivery (Bédard et al., 2009). Although cases of 
successful deliveries in PAH patients on prostacyclin therapy (e.g. epoprostenol) have 
been reported (Bendayan et al., 2005), the general expert consensus is for pregnancy to 
be avoided and contraceptive measures taken. 
 
Conventional therapy 
 Most studies use specific baseline characteristics to measure the efficacy of 
treatment. Improvements in exercise capacity are characterized by 6-minute walk 
distances, an inexpensive, safe clinical test that has been shown to be a strong prognostic 
marker in PAH (Miyamoto et al., 2000). Hemodynamic factors such as pulmonary 
arterial pressure and right ventricular function are also measured. As noted, a 
consequence of advanced PAH is right ventricular failure and subsequent volume 
overload. On this basis, diuretics have been employed to reduce blood volume and right 
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ventricular preload, offering notable improvements in patients with right heart failure 
(Humbert et al., 2004). Often a loop diuretic is first choice, usually furosemide or 
torsemide (Murray et al., 2001), or intravenous diuretics in the case of poor absorption 
(Barst, 2008). 
 While warfarin has been known to have a myriad of drug interactions (Holbrook 
et al., 2005; Spangler and Saxena, 2010), it has been indicated as an effective PAH 
therapy. Dysfunction in endothelial and platelet function leads to increased intravascular 
thrombosis in PAH patients, with related elevation of plasma clotting factors (Humbert et 
al., 2004). Thrombotic lesions are routinely found in pulmonary blood vessels of PAH 
patients (Moser et al., 1995; Hervé et al., 2001) and disease progression may be 
accelerated by platelet release of vasoconstrictors and vascular remodeling agents, such 
as thromboxane A2 and serotonin (Humbert et al., 2004). Unfortunately, the effectiveness 
of warfarin as a PAH therapeutic has been evaluated in few studies with relatively small 
sample sizes (Frank et al., 1997; Rich et al., 1992; Fuster et al., 1984). In all three, use of 
anticoagulants improved survival time in PAH patients, leading many experts to 
recommend the use of warfarin with a target international normalized ratio between 1.5 
and 2.5 (Barst, 2008; Humbert et al., 2004; McLaughlin and McGoon, 2006). More 
research is needed to solidify guidelines for warfarin therapy, particularly when used in 
combination with modern drugs.  
 Another approach to PAH treatment has been the use of calcium channel blockers 
(CCBs). Vascular smooth muscle cells require an influx of calcium to initiate contraction, 
the rationale for CCB therapy involves the blocking calcium channels to reduce 
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vasoconstriction in pulmonary arteries. However, the use of CCBs in PAH treatment 
remains somewhat controversial. Not all patients react favorably, with one study showing 
that only half of IPAH patients responsive to CCBs benefited from long term therapy 
after a 5-year period (Sitbon et al., 2003). In addition, reactivity tests to acute vasodilators 
must be done to identify patients who may benefit from CCB therapy, requiring cardiac 
catheterization and intravenous administration of prostacyclin or inhalation of NO 
(Sitbon et al., 1995). Many patients do not respond to CCBs at all (i.e. chronic 
responders), and as such administration of CCBs may cause negative side effects without 
providing any benefit to the patient.  
 
Prostacyclin therapy 
 While the treatments described above have been at the frontline of pulmonary 
hypertension treatment, recent and exciting advancements in the understanding of PAH 
have led to more targeted therapies. New therapeutics designed specifically to target the 
pulmonary arterial vasculature have shown considerable promise in decreasing side 
effects and mortality rates and ushering patients in a modern era of PAH treatment. 
Among these, therapeutics targeting the prostacyclin pathway have shown favorable 
outcomes in clinical trials. While new medications, with more favorable dosing regimes 
and routes of administration, targeting this pathway have been recently approved by the 
FDA, prostacyclin drugs for PAH patients have existed for some time. 
 Among the first prostacyclin-targeted drugs emerged in the 1980s, epoprostenol. 
Epoprostenol is a prostacyclin agonist which has antiproliferative, antithrombotic, and 
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vasodilator effects (McLaughlin et al., 1998). While this pharmaceutical has been a 
shown to considerably improve patient function, especially in those unresponsive to 
conventional therapy, a major drawback of the medication is the risk for adverse 
complications, such as sepsis and thromboembolism (McLaughlin et al., 1998), due to its 
short half-life requiring continuous intravenous administration by a permanent venous 
catheter. Studies have shown that, compared to conventional therapy alone, epoprostenol 
can significantly improve patient exercise capacity, reduce pulmonary blood pressure and 
vascular resistance, and boost patient survival rates (Barst et al., 1996; Rubin et al., 
1990). Historically, epoprostenol therapy made a substantial impact on PAH patient 
outcomes: one study found that 70% of patients were removed from a lung 
transplantation waiting list due to clinical improvements on intravenous epoprostenol 
monotherapy (Conte et al., 1998). Indeed, lack of alternative targeted therapies and 
considerable improvements over conventional therapies allowed intravenous 
epoprostenol to become a frontline therapy in advanced cases of PAH. 
 Treprostinil is a more stable prostacyclin agonist which can be administered via 
continuous subcutaneous infusion, avoiding the risks associated with intravenous 
epoprostenol administration. While most improvements were seen with high dosing 
regimes, placebo-controlled studies confirmed the benefits of treprostinil therapy on 
exercise capacity: 6-minute walk distances improved by a modest 16 m (Simonneau et 
al., 2002). However, 85% of patients reported pain at the infusion site and 8% terminated 
their treatment altogether (Simonneau et al., 2002). In other studies, as many as 23% of 
patients terminated treprostinil therapy due to adverse side effects (Barst et al., 2006). 
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Due to the frequency of pain at the subcutaneous infusion site, an intravenous treprostinil 
therapy was approved for PAH treatment in 2004. A longer half-life allowed intravenous 
treprostinil significant benefits over intravenous epoprostenol, such as stability at room 
temperature and a higher safety profile should infusion be abruptly interrupted 
(Gomberg-Maitland et al., 2005). While much higher doses were needed, i.v. treprostinil 
showed a similar efficacy when compared to epoprostenol (Gomberg-Maitland et al., 
2005). Still, a therapeutic option convenient for out-patient PAH management remained 
elusive. 
 A novel therapy was approved by the FDA in 2004 which involved the oral 
inhalation of a long-acting prostacyclin analogue. Iloprost was developed to circumvent 
the adverse effects related to continuous infusion and increase selectivity for the 
pulmonary vasculature. It is administered via jet or ultrasonic nebulizers, but due to its 
relatively short half-life it must be given 6 to 9 times daily (Hoeper et al., 2000). Studies 
found fewer systemic side effects and a longer duration of pulmonary vasodilation when 
compared to intravenous prostacyclins (Olschewski et al., 2002). Long term 
observational studies did show improvements to 6-minute walk distances of up to 75 m in 
some patients, and improvements to physical capacity and hemodynamics were sustained 
over 12 months (Hoeper et al., 2000). Inhaled iloprost may be an inexpensive, safer 
option when compared to a permanent venous catheter, with few patients reporting mild 
adverse effects and no patients discontinuing use in clinical studies (Hoeper et al., 2000).  
 Beraprost was the first oral prostacyclin therapy available and has vasodilating, 
antiproliferative, and antiplatelet effects similar to intravenous epoprostenol, but with a 
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much longer half-life (Nishio and Kurumatani, 2001). The prospect of a treatment option 
without continuous infusion or multiple daily inhalations was attractive to physicians and 
patients alike, as it would avoid many potential complications associated with 
conventional prostacyclin administration. Beraprost showed considerable improvement in 
managing acute disease progression, with patients showing an improvement in 6-minute 
walk distance of 25 m (Galiè et al., 2002). This effect, however, was not evident after 12 
months, and patients did not show a slowed disease progression compared to placebo at 
12 months (Barst et al., 2003). Beraprost may be an effective treatment in managing 
symptoms in early PAH, but its efficacy seems to decline over chronic use. Mild adverse 
effects, such as headaches, jaw pain, and nausea, were reported in the majority of 
patients, and 3% discontinued use due to these effects (Barst et al., 2003). These findings 
also emphasize the importance of the length of clinical studies of PAH treatments. 
Beraprost might have been inappropriately touted as a hugely beneficial drug had all 
clinical studies lasted only 3 months.  
 
Endothelin antagonist therapy 
 Endothelin-1 has long been implicated in the progression of pulmonary 
hypertension, with PAH patients having significantly elevated plasma levels. ET-1 is 
thought to exert its hypertensive effects by acting on the ETA or ETB membrane 
receptors on pulmonary smooth muscle to promote vasoconstriction, proliferation and 
hypertrophy (Barst, 2008). It should be noted that activation of the ETB receptor on 
endothelial cells promotes vasodilation and overall clearance of ET-1 from vasculature 
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(Felix et al., 2003). The ultimate effects of ETB antagonism on PAH disease progression 
requires further study, as ETB receptors on endothelial cells may have a protective role 
(Yorikane et al., 1992; Nishida et al., 2004). 
 Bosentan is an orally available ET-1 antagonist at both the ETA and ETB 
receptors. It has been shown to increase 6-minute walk distances by 70 m at 12 weeks 
and reduce both pulmonary arterial pressure and resistance (Channick et al., 2001). Other 
studies found a more modest improvement to 6-minute walk distance of 44 m after 16 
weeks (Rubin et al., 2002). While a benefit of bosentan therapy over epoprostenol is the 
avoidance of potentially complicated continuous infusion, combination therapy may be 
more efficacious than either therapy alone (Humbert et al., 2004). The drug carries the 
potential for many adverse effects, particularly hepatic toxicity and elevated levels 
aminotransferases (Rubin et al., 2002). The adverse effects on the liver are thought to be 
mediated through a drug-induced increase in cytotoxic bile salts (Fattinger et al., 2001).  
Patients must be monitored while receiving treatment with follow-up liver function and 
hematocrit tests. In addition, pregnancy becomes an issue with this therapy due not only 
to bosentan’s teratogenic effects but its interaction with traditional hormone-based 
contraceptions (Dhillon, 2009), requiring women to use alternatives to avoid pregnancy. 
 Sitaxsentan is a selective ETA receptor antagonist given once daily. Due to its 
increased selectivity for the ETA receptor compared to bosentan, sitaxsentan was thought 
to be advantageous due to a lack of inhibition to the potentially protective endothelial cell 
ETB receptor pathway. However, a study found comparable improvements in exercise 
capacity between bosentan and sitaxsentan treatments, increasing 6-minute walk distance 
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by 29.5 m and 31.4 m, respectively (Barst et al., 2006). A long term study was able to 
show that patients on sitaxsentan had an 8% higher survival rate when compared to 
bosentan therapy over 1 year (Benza et al., 2008). In fact, a small sample study found that 
patients with elevated transaminases due to bosentan treatment were able to stabilize 
plasma transaminase levels by transitioning to sitaxsentan (Benza et al., 2007). Still, the 
safety profile for sitaxsentan was a concern for regulators and the drug was voluntarily 
withdrawn from clinical trials before reaching the US market due to fatalities related to 
liver damage (Galiè et al., 2011). Hepatic injury and elevated aminotransferase levels are 
a major concern with the endothelin-1 antagonist class of drugs (Barst et al., 2006). 
 Similar to sitaxsentan, ambrisentan is a once-daily oral ETA-selective endothelin 
antagonist. It shows a lower incidence of liver abnormalities, with one study showing that 
261 patients receiving ambrisentan did not develop elevated aminotransferase levels 
(Galiè et al., 2008). While ambrisentan may be a safer alternative in terms of liver injury 
when compared to bosentan, it may cause clinical worsening in patients with pulmonary 
fibrosis (Raghu et al., 2013). In PAH patients, ambrisentan therapy was shown to 
increase 6-minute walk distance by 45 m over 12 weeks and significantly delay disease 
progression (Galiè et al., 2008). Improvements were sustained over long term treatment, 
with patients showing increases in 6-minute walk distances of 28 m and 23 m after 1 year 
and 2 years, respectively (Oudiz et al., 2009). In fact, most patients showed either an 
improvement of sustainment of their WHO functional class over 2 years of treatment 
(Oudiz et al., 2009), indicating this therapeutic may be beneficial with minimal adverse 
effects, particularly in combination therapy. 
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 While these drugs represent a rational avenue for PAH treatment, targeting the 
endothelin-1 pathway has proved difficult in many ways. Notably, hepatotoxicity remains 
a major concern. Decreases in hematocrit (Barst, 2008) also require further investigation, 
along with interactions with the metabolism of warfarin (Walker et al., 2009). As noted, 
pregnancy can be fatal for some PAH patients and ET-1 antagonists may reduce the 
efficacy of certain contraceptives while also causing teratogenic harm in animal models 
(Barst, 2008). Physicians must carefully weigh the benefits and side effects before 
commencing treatment by this pathway, and monitor patients accordingly. 
 
Phosphodiesterase-5 Inhibitors 
 Phosphodiesterase-5 inhibitors act by potentiating the effects of the NO pathway. 
NO itself is commonly used as an agent for vasoreactivity tests for consideration of CCB 
therapy. PDE genes are up-regulated in cases of pulmonary hypertension (Maclean et al., 
1997). The rationale for PDE-5i agents in pulmonary hypertension therapy is to prolong 
the cGMP-mediated NO signaling pathway, effectively lowering intracellular calcium 
levels and reducing contraction of vascular smooth muscle cells. 
 Sildenafil was initially researched for the treatment of hypertension, but found 
resounding commercial success as the first oral therapy for erectile dysfunction. It acts as 
a selective PDE-5i, prolonging the effects of local NO produced by endothelial cells 
(Goldstein et al., 1998) allowing vasodilation and aiding in proper ventilation-perfusion 
matching in the lungs. Early studies showed that treatment with sildenafil was able to 
prevent pulmonary hypertension in hypoxic mice models (Zhao et al., 2001). Further 
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clinical trials were able to show an increase in 6-minute walk distance of 45m after 12 
weeks of sildenafil, and significant improvements to both pulmonary arterial pressure and 
resistance (Galiè et al., 2005). Furthermore, a 12 month follow-up showed mild adverse 
side effects with sildenafil therapy, and continued, albeit modest, improvements to 
exercise capacity (Galiè et al., 2005). Combination therapy also shows considerable 
promise, as sildenafil combined with inhaled iloprost was found to significantly improve 
both hemodynamics and 6-minute walk distances in patients deteriorating on iloprost 
therapy alone (Ghofrani et al., 2003). In addition, while PAH in children is relatively 
rare, researchers were able to show a remarkable increase in 6-minute walk distances and 
a lowering of pulmonary artery pressure by 10 mmHg over 12 months (Humpl et al., 
2005). This PDE-5i therapeutic seems to represent a safe, affordable therapy (Michelakis 
et al., 2003) with a more convenient route of administration compared to prostacyclin 
pharmaceuticals and without some of the adverse side effects related to targeting the ET-
1 pathway. 
 Tadalafil is an alternative to sildenafil with the advantage of once-daily dosing, 
but only showing efficacy at higher doses (Galiè et al., 2009). Patients showed modest 
improvements in 6-minute walk distances over four months, and these effects were 
sustained over 52 weeks (Oudiz et al., 2012). While this treatment seemed to delay the 
worsening of symptoms, the majority of patients experienced some adverse events (most 
commonly mild to moderate headaches), and up to 25% of patients experienced serious 
adverse events (Oudiz et al., 2012). Tadalafil appears to be a viable therapeutic option for 
patients unresponsive to sildenafil. However, further research is needed to evaluate the 
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long term efficacy and safety of tadalafil compared to sildenafil in chronic treatment 
plans. 
 
Combination Therapy 
 Intravenous epoprostenol remains a frontline therapy for severe cases of PAH, but 
unfortunately, guidelines for physicians in terms of combination therapies are often 
convoluted. Different agencies may have similar but conflicting guidelines based on 
varying degrees of evidence. Many patients fail to respond, or progressively stop 
responding, to a single monotherapy and it has been postulated that a combined 
therapeutic treatment algorithm targeting several pathways may be needed for aggressive 
cases of PAH. Unfortunately, many patients show initial improvements to a certain drug 
but continually deteriorate over time; initial clinical trials are often not long enough to 
capture this decline, emphasizing the importance of long follow-up studies.   
 One study followed patients on bosentan monotherapy, and while they showed 
acute improvements in their physical capacities, the patients worsened below baseline 
values over a year (Hoeper et al., 2004). Adjunct therapy with sildenafil, while 
maintaining the same dosing of bosentan, proved effective in improving 6-minute walk 
distances during a follow-up period of 9 months (Hoeper et al., 2004). In a separate study 
examining combination therapy using bosentan, sildenafil, and inhaled iloprost, Hoeper 
and colleagues found a significantly improved 3-year survival rate of nearly 80% (Hoeper 
et al., 2005). 
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 In contrast, combining treprostinil with either an ET-1 antagonist or a PDE-5i did 
not produce significant improvements to patient exercise capacity compared to either 
therapy alone (Tapson et al., 2012). In addition, roughly 22% of patients discontinued 
treatment due to adverse side effects (Tapson et al., 2012). These results underline the 
importance of studying the efficacy of combination therapies over the long term, as the 
added potential for adverse side effects may offset any modest therapeutic benefits. In 
fact, combination therapies involving guanylate cyclase enhancers and PDE-5 inhibitors, 
both acting through the NO pathway, is contraindicated in PAH patients due to the risk of 
fatal adverse effects (Enderby and Burger, 2015). 
 The value in combination treatment, particularly in advanced cases or 
unresponsive patients, cannot be overstated as it has the potential to save many lives. In 
some cases, the beneficial effects can be synergistic as opposed to simply additive. For 
example, activation of the ETA receptor by endothelin-1 may inhibit overall NO 
production by vascular endothelial cells (Barst, 2008). Thus, co-administration of a PDE-
5i and sildenafil, an ETA antagonist, may act together to increase NO pathway action and 
synergistically increase efficacy. Other synergistic effects have also been found between 
sildenafil and inhaled iloprost (Ghofrani et al., 2002). 
 Currently, initial therapy for PAH patients in WHO functional classes 1 to 3 
involve administration of CCBs after an acute vasoreactivity test (Galiè et al., 2013). 
Should patients fail the acute vasoreactivity test, or should CCB efficacy diminish due to 
tolerance, treatment recommendations depend on patient WHO functional class. In the 
most advanced cases (WHO functional class 4), intravenous epoprostenol therapy is 
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recommended (Galiè et al., 2013). In WHO functional class 2 or 3 patients, a variety of 
drugs may be started for initial monotherapy at the discretion of the prescriber. Should 
patients fail to adequately improve on monotherapy, physicians should begin sequential 
combination therapy while considering the possibility of lung transplantation (Galiè et 
al., 2013). Combination therapy may be more effective if therapeutics from different 
targeting pathways are added to the initial monotherapy, but close monitoring of side 
effects and drug interactions are needed. Interestingly, unless patients fall within the 
WHO functional class 4 category, no single front-line treatment recommendation is given 
(Galiè et al., 2013) and physicians must weight a variety of patient factors, such as route 
of administration and safety profile of various drugs, in the management of PAH. 
 
Emerging and Future Treatments 
 Selexipag is an orally available IP prostacyclin receptor agonist which was 
approved by the FDA for PAH treatment in 2015 (Chakinala et al., 2017). It boasts an 
increased selectivity for the pulmonary vasculature over other prostacyclin medications 
due to its low affinity for non-IP prostanoid receptors (Asaki et al., 2015), minimizing 
systemic side effects. A phase 3 placebo-controlled clinical trial was able to demonstrate 
that treatment with selexipag slowed disease progression and reduced hospitalizations; 
however, it did not significantly affect mortality rate (Sitbon et al., 2015). Another study 
found that pulmonary arterial pressure could be reduced by nearly a third if selexipag was 
added in combination with drugs targeting other pathways (Simonneau et al., 2012). 
Selexipag represents a novel prostacyclin treatment for PAH patients, with promise of a 
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convenient dosing regime and lower risk for adverse side effects when compared to 
similar drugs in its class. Further research and pharmacovigilance is needed to assess the 
efficacy of chronic selexipag treatment. 
 Riociguat is an exciting and relatively new drug approved by the FDA in 2013; it 
is the first drug in its class to be approved for the treatment of WHO PH group 1 and 4 
(Makowski et al., 2015). It acts as a soluble guanylate cyclase enhancer, increasing the 
levels of cGMP independently of the local availability of NO. This may provide an 
advantage over traditional PDE-5i therapy as PAH patients have lower levels of NO 
synthase (Ghosh et al., 2016), lowering overall NO production in the pulmonary 
vasculature. Phase 3 trials of riociguat have shown an increase in patient 6-minute walk 
distance of 36 m, as well as significant improvements to arterial resistance and pressure 
in the pulmonary vasculature (Ghofrani et al., 2013). A follow-up study also found that 6-
minute walk distances continued to improve in patients for up to 24 weeks and 
significantly lengthened the time until patients suffered symptomatic worsening 
(Ghofrani et al., 2013). Although this novel therapeutic represents an exciting approach 
to PAH treatment, the clinical use of riociguat has several drawbacks. The drug has been 
shown to be teratogenic in animal models, and is therefore contraindicated in pregnant 
women (Makowski et al., 2015). Although rare, serious bleeding and hemorrhagic events 
may also occur, and the drug cannot be used in conjunction with PDE-5i therapy due to 
drug interactions (McLaughlin et al., 2015). Cost may also be a limiting factor for use, 
with prices nearing $90,000 (Makowski et al., 2015).  
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 Imatinib has been approved by the FDA as a chemotherapy agent for well over a 
decade; its effectiveness in PAH treatment is an emerging topic. Imatinib is a tyrosine 
kinase inhibitor currently used in the treatment of certain cancers, such as chronic 
myelogenous leukemia and acute lymphocytic leukemia. Its rationale for PAH treatment 
revolves around the vascular remodeling seen in the pulmonary circuit, particularly the 
disorganized proliferation of smooth muscle cells and fibroblasts seen in PAH (Humbert 
et al., 2004). Therefore, it is hypothesized that inhibition of growth factors, such as 
platelet-derived growth factor (PDGF), may reverse the effects of pulmonary vascular 
remodeling and provide an antiproliferative treatment for PAH. There have been several 
case reports showing efficacy of imatinib in PAH treatment, particularly in patients 
unresponsive to traditional therapies or with rapidly deteriorating conditions despite 
treatment (Ghofrani et al., 2005; Souza et al., 2006). Studies also showed that the drug 
could improve 6-minute walk distances by 36 m and modestly improve hemodynamics in 
patients already on combination therapy (Hoeper et al., 2013). Further research is needed 
on the long term efficacy of using imatinib, particularly its effects on patient mortality, 
and as well as its safety profile in PAH patients.  
 Macitentan is a therapeutic directed against the ET-1 pathway approved by the 
FDA for PAH treatment in 2013. It is a dual ETA-ETB receptor antagonist taken once 
daily, and has a lower incidence of hepatotoxicity compared to other ET-1 antagonists 
(Raghu et al., 2013). Therapy was shown to significantly delay worsening of symptoms, 
and it also reduced death rates due to PAH by 13% when compared to a placebo group 
(Pulido et al., 2013). Patients also showed a modest improvement in 6-minute walk 
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distances and hemodynamic factors (Pulido et al., 2013); however, improvements were 
not as significant compared to results from other, more traditional therapies. While the 
therapy may show promise due to the lack of side effects normally associated with 
endothelin-1 antagonists, further research is needed on its value as an efficacious 
treatment option when used in combination. 
 
Genetic Therapy 
 While great advancements have been made over the last two decades regarding 
targeted PAH therapy, there is still ample room to improve patient outcomes and 
mortality rates. Advancements in therapeutics, particularly those with reduced off-target 
effects and with an easier route of administration, have helped patients cope with 
pulmonary hypertension. Approaching treatment from a multifactorial view and 
addressing all three pathways implicated in pulmonary hypertension pathology may offer 
the best hope at slowing disease progression. It seems that no single pathway is entirely 
responsible for the disease progression in PAH, and dysfunction in more than one 
pathway may be the ultimate cause. Already, novel therapeutics and new research into 
the efficacy of combination therapies have shown to considerably improve patient quality 
of life, particularly in those patients unresponsive to traditional therapies. The rationale 
for recent advancements has largely been driven by the observation of an imbalance in 
endothelial-derived vasoconstrictors over vasodilators. Genetic therapy has the potential 
to address this pathobiology at its root, potentially reversing the effects of PAH on the 
pulmonary vascular structure. Since most patients present at the clinic once symptoms 
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worsen and the disease has progressed to a late stage, reversing the vascular changes 
caused by PAH may be much more efficacious than preventing further remodeling. 
 Although genetic therapy may offer the best hope of curing PAH in the future, 
current research in a clinical setting is limited. It is well known that the BMPR2 gene is 
closely related to the occurrence of FPAH, and may be implicated in a minority of IPAH 
cases as well (Newman et al., 2004). In fact, up to 70% of FPAH cases and 10-40% of 
IPAH cases are correlated with mutations in the BMPR2 gene (Sztrymf et al., 2008). To 
further complicate this matter, patients with BMPR2 mutations may also respond poorly 
to vasoreactivity tests (Sztrymf et al., 2008), excluding them from conventional therapies 
such as oral CCBs. As such, genotyping of patients at risk for PAH for mutations in 
BMPR2 may prove a useful diagnostic tool for future physicians. A definitive marker for 
poor prognosis in PAH patients is entering treatment at WHO functional class 3 and 
above; by identifying at-risk patients with the potential to develop PAH before 
widespread pulmonary vasculature remodeling has taken place, physicians may be able to 
drastically improve outcomes with the currently available therapies. 
 The importance of the BMPR2 gene in hereditary PAH should be strongly 
emphasized as it represents a novel approach to treatment. Animal models were able to 
show that deletion of the BMPR2 gene in endothelial cells was sufficient to induce 
symptoms of PAH (Hong et al., 2008). Protein replacement therapy and other genetic 
options are future pathways in which PAH research should be directed. A major ligand 
for BMPR2 is the bone morphogenetic protein (BMP), of which there are many subtypes. 
Researchers were able to show that increasing the concentration of BMP can overcome 
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the loss of function related to mutations in BMPR2 gene, in vitro (Yang et al., 2008). 
Thus, administration of a BMP ligand with high selectivity for the pulmonary 
endothelium may represent a novel approach to PAH treatment. Recent studies showed 
that administering BMP9 could not only reverse the effects of vascular remodeling found 
in mice with BMPR2 mutations, but enhance BMPR2 gene expression as well (Long et 
al., 2015). Future genetic research is needed to shed light on the complexity associated 
with this concept in human subjects. 
 Another gene which may be targeted for PAH treatment is survivin. Survivin is a 
member of the inhibitor of apoptosis (IAP) protein family and its increased expression is 
often associated with malignant cancers (Jaiswal et al., 2015). Interestingly, researchers 
found high levels of survivin in the pulmonary vasculature of patients with PAH 
(McMurtry et al., 2005). Furthermore, they were able to show survivin expression 
increases with increasing pulmonary arterial pressure. By suppressing endogenous 
survivin levels in the rat, researchers were able to reverse the adverse vascular 
remodeling and significantly improve survival rates (McMurtry et al., 2005). Its 
differential expression in the remodeled vasculature associated with PAH and relative 
absence in normal tissue makes survivin an appealing target for future therapies. There 
are a host of other potentially exciting areas of research in terms of genetic therapies for 
PAH. Researchers were able to show that injection of endothelial progenitor cells 
transfected with functional NO synthase could repair the vascular remodeling seen in 
PAH, and significantly reduce mortality rates in animal models (Zhao et al., 2005). The 
excitement surrounding cell-replacement therapies are indicative of their potential to 
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reverse the damage done by disease progression. Transfected endothelial progenitor cells 
were injected into PAH patients in a phase 1 clinical study: patients showed reduced 
arterial pressure, significantly improved physical capacity, and relatively low incidence 
of adverse effects (Granton et al., 2015). 
 Although genetic therapy as a treatment of PAH is in its infancy, advancements in 
research offer patients a glimpse towards a cure and the future of PAH management. To 
date, substantial advancements have been made in delivering targeted pharmaceuticals to 
patients, but most drugs act to prevent further deterioration of the pulmonary vasculature 
and do not reverse the effects of dysfunctional endothelial-driven arterial remodeling. A 
particular challenge in the clinical treatment of PAH is diagnosis: most patients do not 
present until the disease has progressed far enough to cause symptoms. Therefore, early 
diagnosis by biomarkers may be instrumental in improving patient outcomes with 
conventional therapies. With accelerated research and funds devoted to this disease, we 
may be able to significantly improve quality of life and prognosis for patients. 
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